Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 16/20 | 1.00 |
| ▸ | HCRTR2 | O43614 | 16/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ATP4A | P20648 | 1/20 | 0.40 |
| ▸ | ATP4B | P51164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4793114 | 0.93 | HCRTR1 (0.87) | HCRTR1HCRTR2KDM4ESMN1; SMN2ATP4A | |
| SCHEMBL4768122 | 0.91 | HCRTR1 (0.84) | HCRTR1HCRTR2KDM4ESMN1; SMN2 | |
| SCHEMBL4842824 | 0.90 | HCRTR1 (0.82) | HCRTR1HCRTR2 | |
| SCHEMBL4795204 | 0.88 | HCRTR1 (0.79) | HCRTR1HCRTR2KDM4ESMN1; SMN2 | |
| SCHEMBL4792563 | 0.88 | HCRTR1 (0.78) | HCRTR1HCRTR2 | |
| SCHEMBL4793604 | 0.86 | HCRTR1 (0.76) | HCRTR1HCRTR2 | |
| SCHEMBL4768695 | 0.85 | HCRTR1 (0.73) | HCRTR1HCRTR2 | |
| SCHEMBL4773029 | 0.84 | HCRTR1 (0.72) | HCRTR1HCRTR2 | |
| SCHEMBL4795370 | 0.82 | HCRTR1 (0.70) | HCRTR1HCRTR2 | |
| SCHEMBL4795690 | 0.80 | HCRTR1 (0.66) | HCRTR1HCRTR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | claimed |
| EP-1871752-A1 | AMIDOPROPOXYPHENYL OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-01-02 | — | — | EP | claimed |
| WO-2006110626-A1 | AMIDOPROPOXYPHENYL OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-10-19 | — | — | WO | claimed |
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | disclosed |
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | disclosed |
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885KDM4E 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.